

CLAIMS

1. Use of a TACI-Fc fusion protein in the manufacture of a medicament for treating Sjogren's syndrome (SS), wherein the TACI-Fc fusion protein comprises:

- (i) a TACI extracellular region or a fragment thereof binding to Blys and/or APRIL; and
- (ii) a fragment of human immunoglobulin constant region.

2. The use according to claim 1, wherein the TACI extracellular region or the fragment thereof binding to Blys and/or APRIL comprises an amino acid sequence set forth in SEQ ID NO: 1.

3. The use according to claim 2, wherein the human immunoglobulin is IgG1, or the fragment of human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, or at least 96% identity to SEQ ID NO: 2.

4. The use according to claim 3, wherein the fragment of human immunoglobulin constant region comprises one or more modifications of amino acid at positions 3, 8, 14, 15, 17, 110, 111 or 173 of SEQ ID NO: 2.

5. The use according to claim 4, wherein the modification is substitution, deletion or insertion of amino acid.

6. The use according to claim 5, wherein the substitution is selected from the group consisting of P3T, L8P, L14A, L15E, G17A, A110S, P111S and A173T.

7. The use according to claim 6, wherein the fragment of human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 3.

8. The use according to claim 1, wherein the TACI-Fc fusion protein has an amino acid sequence set forth in SEQ ID NO: 4.

9. The use according to claim 8, wherein the TACI-Fc fusion protein is Telitacicept.

10. The use according to claim 8 or 9, wherein the Sjogren's syndrome comprises primary Sjogren's syndrome or secondary Sjogren's syndrome.

11. The use according to claim 8 or 9, wherein the TACI-Fc fusion protein is administered at

a single dose of about 0.1 to 10 mg/kg.

12. The use according to claim 8 or 9, wherein the TACI-Fc fusion protein is administered at a single dose of 160 to 240 mg, preferably 160 mg or 240 mg.

13. The use according to claim 12, wherein the TACI-Fc fusion protein is administered subcutaneously, intramuscularly or intravenously, or at the thigh, abdomen or upper arm.

14. The use according to claim 12, wherein the TACI-Fc fusion protein is administered 2-4 times at intervals of one month.

15. The use according to claim 14, wherein the TACI-Fc fusion protein is administered at a frequency of once a week.

16. The use according to claim 14, wherein the administration lasts for about 2-50 weeks.